Dan Stanton

Smaller innovators are more likely to be upended by US legislation aimed at restricting working with China-based CDMOs like WuXi Biologics, according to Latham Biopharm.

Cell therapies will play an increasingly important position in AstraZeneca’s broad oncology pipeline, an SVP told delegates at Biotech Week Boston (BWB) last month.

Diminished destocking and stabilized consumable demand are helping bioprocess vendors return to growth, but the slow recovery in funding remains a headwind.

Aurigene’s chief commercial officer says his firm and other Indian CDMOs are “a very viable alternative” if major Chinese manufacturers are removed from the US biopharma supply chain.

GHO Capital Partners and Ampersand Capital Partners will increase their presence in the biomanufacturing space through the planned acquisition of Avid.

Andrew Mears, CEO of Lead Candidate, highlighted a dichotomy in the industry, where some sectors are downsizing while others are experiencing rapid growth during a video interview at Biotech Week Boston (BWB).

2025 will see increased biotech IPOs, spurred on by a “flight to quality” and declining interest rates, says William Blair analyst Kevin Eisele.

While much talk at CPHI Milan centered on the potential impact of BIOSECURE, other US policies – particularly the Inflation Reduction Act (IRA) – are proving a boon for Indian CDMOs.

CSL Behring will deprioritize ex vivo lentiviral-based gene therapies and shutter a facility in California as it converges its advanced therapy R&D operations to Waltham, Massachusetts.

The proposed acquisition of Evotec would essentially transform Halozyme from a therapeutics-based drug delivery platform into a full bioprocess services company.